Favezelimab

Merck discontinues vibostolimab and favezelimab clinical programs after Phase 3 trials met futility criteria. Vibostolimab/pembrolizumab combination showed no new safety signals but more immune-related adverse events. Favezelimab/pembrolizumab trial in Hodgkin lymphoma also halted. Merck prioritizes other programs with greater potential to improve cancer outcomes.

Merck discontinues vibostolimab and favezelimab clinical programs due to futility in Phase 3 trials. FDA accepts Merck's BLA for clesrovimab, targeting RSV protection in infants, with a decision expected by June 2025.

Merck discontinued KeyVibe and KEYFORM programs for vibostolimab and favezelimab after clinical setbacks. Both drugs, tested with Keytruda, failed to meet primary endpoints in late-stage studies. Keytruda remains Merck's top revenue driver, with sales over $21 billion in 2024. Merck's stock has underperformed, losing 8.3% year to date.

Merck & Co., Inc. halts clinical trials for vibostolimab and favezelimab, anti-TIGIT and anti-LAG-3 antibodies, respectively, due to futility in Phase 3 trials. Vibostolimab was tested with pembrolizumab in NSCLC, and favezelimab with pembrolizumab in cHL. No new safety issues were found. Merck will focus on other oncology pipeline candidates.

Merck discontinues clinical development of vibostolimab and favezelimab, citing futility in Phase 3 trials. KeyVibe-003 and KeyVibe-007 met futility criteria for overall survival in non-small cell lung cancer. Safety profiles were consistent with prior studies. KEYFORM-008 enrollment halted for relapsed or refractory Hodgkin lymphoma. Merck prioritizes other oncology candidates.

Merck halts clinical trials for vibostolimab and favezelimab, anti-TIGIT and anti-LAG-3 antibodies, due to futility in Phase 3 trials for non-small cell lung cancer and relapsed/refractory classical Hodgkin lymphoma. Safety profiles were consistent with previous studies, with no new safety signals. Merck prioritizes other oncology pipeline candidates.

Merck announced the discontinuation of clinical development programs for vibostolimab and favezelimab, anti-TIGIT and anti-LAG-3 antibodies, respectively. This decision follows Phase 3 trials meeting futility criteria for overall survival in NSCLC and a thorough evaluation of favezelimab data. Merck will prioritize other oncology pipeline candidates, ensuring patient safety and informing investigators and patients about next steps.

Merck discontinues vibostolimab and favezelimab clinical programs due to futility in Phase 3 trials, prioritizing other oncology candidates.